Related Content

• Conditions (26): Lymphoma, Testicular Neoplasms, Lymphoma, Non-Hodgkin's, and 23 others Lymphoma, Testicular Neoplasms, Lymphoma, Non-Hodgkin's, Lung Neoplasms, Ewing's Sarcoma, Multiple Myeloma, Mammary Neoplasms, Thrombocytopenia, Hodgkin Disease, Rhabdomyosarcoma, Lupus, Acute Myelogenous Leukemia, Kaposi Sarcoma, Autoimmune Hemolytic Anemia, Multiple Sclerosis, Brain Tumors, Trophoblastic Neoplasms, Acute Lymphocytic Leukemia, Neutropenia, Neuroblastoma, Melanoma, Waldenstrom Macroglobulinemia, Squamish Cell Skin Cancer, Soft Tissue Sarcoma, Psoriasis, Cutaneous T-Cell Lymphoma [hide]
• Groups (37): Mycosis Fungoides, Melanoma, Eczema, and 34 others Mycosis Fungoides, Melanoma, Eczema, Lymphoma, Beckers Nevus, Lichen Planus, Lichen Sclerosis, Darier's Disease, Hidradenitis Suppurativa, Granuloma Annulare, Alopecia Areata, Sweet Syndrome, Ovarian Cancer, Acne Rosacea, Large Granular Lymphocyte Leukemia, Liposarcoma, Bladder Cancer, Leiomyosarcoma, Pancreatic Cancer, Astrocytoma, Acute Lymphocytic Leukemia, Burkitt's Lymphoma, Esophageal Cancer, Uterine Carcinosarcoma, Brain Tumors, Cholangiocarcinoma, Inflammatory Breast Cancer, Brain Cancer, Testicular Cancer, Lung Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Children of Cancer Victims and Survivors, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Light The Night Walk in New York City, Australian Lymphoma Support Group [hide]
• Symptoms (17): Decreased DNA Integrity, Decreased DNA Replication, Graft Rejection, and 14 others Decreased DNA Integrity, Decreased DNA Replication, Graft Rejection, Hepatic Metabolism, Histiocytosis, Edema, Decreased Respiratory Secretion Viscosity, Increased Intravascular Volume, Hyponatremia, Shock, Hemorrhagic, Alveolar Surface Tension Reduction, Granuloma Annulare, Alopecia Areata, abnormal growth and differentiation, Raynaud's Disease and Phenomenon, red skin rash, Angioedema [hide]
• Treatments (26): Cyclophosphamide, Alkylating Agents, Methotrexate, Sodium Salt, and 23 others Cyclophosphamide, Alkylating Agents, Methotrexate, Sodium Salt, Nucleic Acid Synthesis Inhibitors, Etoposide, Interferon Alfa-2a, Thymidylate Synthetase Inhibitors, Dihydrofolate Reductase Inhibitors, Methotrexate 25 MG/ML Injectable Solution, CYCLOPHOSPHAMIDE 100 MG, Mechlorethamine, Etoposide 20 MG/ML Injectable Solution, Cyclophosphamide 25 MG/ML Injectable Solution, Cyclophosphamide 20 MG/ML Injectable Solution, Cyclophosphamide 50 MG, Vinblastine, CYCLOPHOSPHAMIDE 200 MG, Vinblastine Sulfate, Cisplatin, Cyclophosphamide 50 MG Oral Tablet, Methoxsalen, Vinblastine 1 MG/ML Injectable Solution, Cyclophosphamide 20 MG/ML / Mannitol 15 MG/ML Injectable Solution, Mechlorethamine hydrochloride, Dacarbazine, Antineoplastic Agents [hide]

About Mycosis Fungoides

Mycosis Fungoides (also known as Alibert-Bazin syndrome or granuloma fungoides), is a rare form of cutaneous T-cell non-Hodgkin's lymphoma. It generally affects the skin, but may progress internally over time. Mycosis Fungoides was first described in 1806 by French dermatologist Jean-Louis-Marc Alibert. The... more

Mycosis Fungoides (also known as Alibert-Bazin syndrome or granuloma fungoides), is a rare form of cutaneous T-cell non-Hodgkin's lymphoma. It generally affects the skin, but may progress internally over time.
Mycosis Fungoides was first described in 1806 by French dermatologist Jean-Louis-Marc Alibert. The name mycosis fungoides is somewhat confusing because it sounds, to the uninitiated, like a type of fungal infection. In reality, mycosis fungoides is unrelated to fungus and the fungoides portion derives from a patient with a severe case whom Alibert described as having mushroom-like skin tumors.

Origins and causes

The cause of mycosis fungoides is unknown, and is not believed to be hereditary or genetic. It is not contagious.
It is rare for the disease to appear before age 20, and it appears to be noticeably more common in males than females, especially over the age of 50, where the incidence of the disease (the risk per person in the population) does increase. The average age of onset is between 45 and 55 years of age for patients with patch and plaque disease only, but is over 60 for patients who present with tumours, erythroderma (red skin) or a leukemic form (the Sézary syndrome).
The disease is an unusual expression of T-cells, a part of the immune system. These T-cells are skin-associated, meaning that they biochemically and biologically are most related to the skin, in a dynamic manner. Mycosis Fungoides is the most common type of 'Cutaneous T-cell Lymphoma' (CTCL), but there are many other types of CTCL that have nothing to do with Mycosis Fungoides and these disorders are treated differently.

Symptoms, diagnosis, and stages

Typical visible symptoms include rashlike patches, tumors, or lesions. Itching (pruritus) is common, perhaps in 20% of patients, and is not universal.
Diagnosis is sometimes difficult because the early phases of the disease often resemble eczema or even psoriasis. As with any serious disease, it is advisable to pursue the opinion of a medical professional if a case is suspected. Diagnosis is generally accomplished through a skin biopsy. Several biopsies are recommended, to be more certain of the diagnosis. The diagnosis is made through a combination of the clinical picture and examination, and is confirmed by biopsy.
To stage the disease, various tests may be ordered, to assess nodes, blood and internal organs, but most patients present with disease apparently confined to the skin, as patches (flat spots) and plaques (slightly raised or 'wrinkled' spots).

Treatments and cures

Mycosis fungoides can be treated in a variety of ways.
If treatment is successful the disease can go into a non-progressing state with clinically clear examination and various tests. This is called remission; it can last indefinitely. Treatments may also cause disease not to progress, while still present, and this is called stable disease; it may last indefinitely but is a more serious situation. Disease may also progress, to involve nodes, blood and internal organs, or transform into a higher-grade lymphoma.
Common treatments include simple sunlight, ultraviolet light, topical steroids, topical and systemic chemotherapies, local superficial radiotherapy, total skin electron beam radiation, and biological therapies (e.g. interferons, retinoids, rexinoids).Vorinostat (Zolinza®) is a second-line drug for CTCL. Application of organic (Manuka) honey to skin affected by erythorderma (red skin) has also proved to be effective in reducing inflammation. Treatments are often used in combination.
Selection of treatments typically depends on patient preference and access to therapies, as well as recommendations by physicians, the stage of the disease, established resistance to prior therapies, allergies of the patient, clinical evidence of a positive benefit:risk ratio, and so on.
It is debatable whether cures are reliably obtained through different types of treatments, but many patients experience prolonged periods of disease-control and at least half of all patients do not die from this disease, even if not truly cured. Quality of life is a major objective, in addition to cure, and maximizing periods of remission or stable disease, while minimizing treatments and toxicities, are two central concerns in clinical care.

less